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Abstract
Multiple sclerosis (MS), a chronic demyelinating and neurodegenerative disease of the central nervous system
(CNS), whose pathogenesis likely involves an interaction of environmental factors with a genetic predisposition. The
hypothesis that Epstein-Barr virus (EBV), a ubiquitous human γ-herpesvirus may be a causal agent pivots on the
evidence of EBV-specific antibodies high titers in MS patients as compared to controls, and on the observed direct
association between such antibodies titers and disease activity. However, the literature on the possible etiological
role of EBV is conflicting. This commentary aims to provide an overview on the use of EBV-specific antibodies as
biomarkers in MS course.
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Commentary
Multiple sclerosis (MS) is a chronic, inflammatory and
neurodegenerative immune-mediated disease of the central nervous
system (CNS) and the commonest cause of non-traumatic neurological
disability in young adults [1]. Among the main diagnostic features of
MS are: a) clinical spatial and temporal dissemination of neurological
sign and symptoms; b) multi-focal lesions in the periventricular white
matter on Magnetic Resonance Imaging (MRI) scans [2]; c) the
presence of oligoclonal IgG bands (OCB) in cerebrospinal fluid (CSF)
and not in serum, reflecting an intrathecal synthesis of
immunoglobulins [3].
Despite MS etiopathogenesis remains largely unknown, it is
considered a multifaceted demyelinating and neurodegenerative
disorder likely generated by an age-specific interplay between genetic
predisposition and environmental factors [1]. The potential role for an
infectious agent in MS pathogenesis has been supported by
epidemiological evidences [4,5].
Epstein-Barr virus (EBV) is a ubiquitous human γ-herpesvirus
capable to infect, activate, and latently persist in B lymphocytes for the
lifetime of the infected host [6]. Primary infection with EBV is
transmitted through saliva and it is asymptomatic, if occurring in
childhood, or can cause infectious mononucleosis (IM) in puberty or
adulthood [7].
An increasing number of articles have been published in the last
decades on the association between MS and EBV (Figure 1) and special
interest was raised by Serafini and colleagues who demonstrated EBV-
infected infiltrating B lymphocytes in post-mortem brain tissue of MS
patients [8]. However, other groups failed to consistently find EBV-
positive B cells in MS affected brains [9].
Figure 1: Number of articles published per year matching the
searching terms "multiple sclerosis" and "EBV" on PubMed.
The strongest association between MS and EBV still derives from
seroepidemiological investigations (Table 1) suggesting the use of
EBV-specific antibodies as markers of the natural course of the disease
through the longitudinal correlation with known clinical variables
(type 0 biomarkers) [10]. Most such evidences build from the use of
the Epstein-Barr nuclear antigen (EBNA) complex, especially EBNA-1
and the structural protein viral capsid antigen (VCA), as targets of the
humoral response. EBNA-1 is the only EBV-encoded protein expressed
in proliferating EBV-infected memory B cells and it maintains EBV
infection by distributing viral DNA into progeny cells during cell
division [11]. VCA is expressed during acute infection or following
occasional reactivations of the lytic cycle [12]. Elevated EBV-specific
antibodies titers have been reported more commonly in MS patients
than in controls, preceding and predicting the development of the
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disease and of its progression, and were intrathecally produced in MS
patients [8,13-25].
Biomarker Correlation (Target antigens)
EBV-specific
antibodies in serum
More elevated in MS patients than in controls (EBNA-1)
[13]
 
Elevated in serum of pediatric MS patients (EBNA and
VCA) [14,15]
 
More elevated before the onset of the disease (EBNA-2)
[16]
 Robust marker of MS risk (EBNA) [17]
 
Increased in CIS patients; predicted conversion to MS;
correlated to disease progression (EBNA-1) [18, 19]
 
Associated to grey matter atrophy (VCA) [20] and to
cortical atrophy and lesion burden (EBNA-1 and VCA) [21]
EBV-specific
antibodies in CSF
Intrethecally synthesized (AI positive) more in MS than in
controls (EBNA-1 and VCA) [22]
 
CSF EBV-specific OCB in 30% of MS patients (EBNA-1)
[23]
 
CSF EBV-specific OCB in 94% [8], 24% [24] and 14% [25]
of MS patients (all viral antigens)
Table 1: Epstein-Barr virus (EBV) specific antibodies as biological
markers to sustain a causal role for EBV in multiple sclerosis (MS)
pathogenesis (AI: Antibody Index; CIS: Clinically Isolated Syndrome;
CSF: Cerebrospinal Fluid; EBNA: Epstein-Barr Nuclear Antigen; EBV:
Epstein-Barr Virus; MS: Multiple Sclerosis; OCB: Oligoclonal IgG
Bands; VCA: Viral Capsid Antigen).
Notwithstanding a general agreement on the association between
MS and elevated serum concentrations of anti-EBV (especially anti-
EBNA-1 specific) antibodies, other evidences argue against the use of
such antibodies as biomarkers in MS (Table 2). In particular, serum
levels of EBV-specific antibodies were not found to correlate with
disease severity, progression and activity by us [24] and by Ingram et
al. [26] and Gieß et al. [27]. Furthermore, EBV-specific antibodies
concentrations were not shown to be influenced by disease modifying
treatments [28,29], apart from their use in capturing therapeutic
intervention effects implying their mechanism of action (type 1
biomarkers) [10]. Also CSF anti-EBV antibody concentrations did not
correlate with clinical activity, severity and duration and were found
higher in controls than in MS [24,30,31]. Moreover, whereas
intrathecally synthesized, EBV-specific antibodies were infrequent and
with low affinity in MS [24,32]. Of particular interest is indeed the role
of the antibody affinity in the context of MS. High affinity antibodies
specific for the causative agent have been shown in infectious diseases
[33]. Interestingly, the presence of somatic hyper mutation in the
immunoglobulin genes indicates that OCB are composed of high-
affinity antibodies [34]. In a recent work, we found that 24% of MS
patients had EBV-specific IgG OCB in CSF and not in the
corresponding serum, with a great inter-individual variability in
number and intensity [24]. However, all these OCB showed low affinity
for viral proteins, suggesting that they may include cross-reactive
antibodies which are part of a polyspecific intrathecal response where
EBV would not represent the cognate antigen. In the same study, we
found that the antibody affinity was higher for the virus surface
structural virocapsidic antigen, than for the nuclear antigen, released
by dying cells, confirming the EBV intermittent cytopathic behaviour
[24,35].
Biomarker Correlation (Target antigens)
EBV-specific
antibodies in
serum
No differences between MS subgroups (RR, PP, CARR,
CSRR), no correlation with age at onset, disease duration,
EDSS or MSSS (EBNA-1) [26]
 
No correlation with number of MRI lesions, Barkhof criteria,
EDSS, and not association with conversion to clinically
definite MS in CIS/early RR MS (EBNA-1 and VCA) [27]
 
No correlation with disease activity (clinical and MRI) and
disease duration (EBNA-1 and VCA) [24]
 
Not useful for monitoring Natalizumab and interferon-beta
therapy (EBNA-1 and VCA) [28,29]
EBV-specific
antibodies in CSF
No correlation with disease activity (clinical and MRI)
disease severity (EDSS) and disease duration (EBNA-1
and VCA) [24]
 More elevated in OIND than in MS and NIND (VCA) [30]
 
Intrathecal synthesis (AI) almost absent in MS, OIND and
NIND (EBNA-1 and VCA) [24,31]
 
EBV-specific OCB in MS, OIND and NIND as a ‘mirror
pattern’ (all viral antigens) [32]
 
EBV-specific OCB composed by low affinity antibodies (all
viral antigens) [24]
Table 2: Epstein-Barr virus (EBV) specific antibodies as biological
markers to argue against a causal role for EBV in multiple sclerosis
(MS) pathogenesis (AI: Antibody Index; CARR: Clinical Active
Relapsing Remitting Multiple Sclerosis; CIS: Clinically Isolated
Syndrome; CSF: Cerebrospinal Fluid; CSRR: Clinical Stable Relapsing
Remitting Multiple Sclerosis; EBNA: Epstein-Barr Nuclear Antigen;
EBV: Epstein-Barr Virus; EDSS: Expanded Disability Status Scale; MRI:
Magnetic Resonance Imaging; MS: Multiple Sclerosis; MSSS: Multiple
Sclerosis Severity Score; OCB: Oligoclonal IgG Bands; RR: Relapsing
Remitting Multiple Sclerosis; PP: Primary Progressive Multiple
Sclerosis; VCA: Viral Capsid Antigen).
EBV is widespread in the human population, often nearly or
completely asymptomatic. It persists life-long in B cells and
intermittently causes lytic infections. For these reasons the association
between MS and EBV do not fulfil the Koch's Postulates for causality,
yielding discordant results which per se fail to clarify the nature of this
virus-specific humoral immune response.
New hypotheses which could explain the association between EBV
and MS have been proposed [36] and EBV has been indicated as the
possible trigger of an intrathecal reaction that occurs during MS [37].
However, the conceptual frame for EBV-related pathogenetic
mechanism in MS builds on the role of EBV-transformed B
lymphocytes infiltrating the brain, maintaining the intrathecal
production of antibodies [38] and/or acting as resident antigen
presenting cells (APC) sustaining the immune-mediated reaction
within the CNS [39] (Figure 2). This condition may be worsened by the
proliferation of latently infected cells due to the defective CD8+ T-cell
control of EBV reactivation in MS patients [40], resulting in the
maintenance of the autoreactive/pathogenic EBV-infected B cells
reservoir for a lifetime. One indirect evidence of such hypothesis is that
the antibody production in MS CSF is stable overtime [41] and that
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their specificity seems to be unrelated to the disease activity [42] as
consequence of a random EBV-driven B cells transformation [43].
Figure 2: Epstein-Barr virus (EBV) has the ability to infect, activate and latently persist in B lymphocytes through the expression of different
transcription programs. In healthy individuals (left panel), during primary infection, the virus enters the tonsil from the saliva and infects
naïve B cells. EBV, expressing the "growth program" or latent program III, drives out to the resting state naïve B cells to become activated B
blasts which then enter the germinal centers reaction. In this condition EBV express the "default program" or latent program II that stimulate
B blasts to proliferate and differentiate into infected memory B cells that can then recirculate in blood and in which the virus does not express
viral protein (latency) or expresses only the nuclear antigen 1 during cell division. Circulating memory B cells can finally differentiate into
plasma cells which initiates the lytic phase of infection producing free virions. In normal condition, EBV infection is controlled by EBV-
specific cytotoxic (CD8+) T lymphocytes. During multiple sclerosis (right panel) all these processes could involve pathogenetic/autoreactive
naïve B cells. A repertoire of EBV-infected memory B cells could survive in the MS infected host due to an altered CD8+ T cells response to
EBV [40]. Finally, CNS-infiltrating pathogenic plasma cells could contribute to the development and to the maintenance of the
neuroinflammation through the production of oligoclonal IgG bands [9] or acting as antigen presenting cells that stimulate autoreactive CD4+
cells [10]. Red lines and red dashed lines with perpendicular bars indicate normal and defective CD8+ T-cell control respectively. This picture
is mainly based on works published by Thorley-Lawson et al. [6], for the biology of the EBV infection and by Serafini et al. for the dysregulated
EBV infection [8].
In conclusion, EBV remains one of the most important
environmental risk factor for MS with a potential triggering
mechanism in the intrathecal IgG synthesis - MS laboratory hallmark -
and this is still matter of interest. Further research will elucidate the
role of a persistent dysregulated EBV infection and/or of an altered
immune response to EBV in triggering or modulating the risk for MS.
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